DE60120650T2 - Chemoselektive anknüpfung durch verwendung eines phosphins - Google Patents
Chemoselektive anknüpfung durch verwendung eines phosphins Download PDFInfo
- Publication number
- DE60120650T2 DE60120650T2 DE60120650T DE60120650T DE60120650T2 DE 60120650 T2 DE60120650 T2 DE 60120650T2 DE 60120650 T DE60120650 T DE 60120650T DE 60120650 T DE60120650 T DE 60120650T DE 60120650 T2 DE60120650 T2 DE 60120650T2
- Authority
- DE
- Germany
- Prior art keywords
- molecule
- phosphine
- group
- cell
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 title claims abstract description 188
- 229910000073 phosphorus hydride Inorganic materials 0.000 title claims abstract description 87
- 210000004027 cell Anatomy 0.000 claims abstract description 175
- 238000006243 chemical reaction Methods 0.000 claims abstract description 98
- 150000001540 azides Chemical class 0.000 claims abstract description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 34
- 150000001413 amino acids Chemical class 0.000 claims abstract description 27
- 230000004962 physiological condition Effects 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 54
- 239000000376 reactant Substances 0.000 claims description 48
- -1 aryl amide Chemical class 0.000 claims description 43
- 235000000346 sugar Nutrition 0.000 claims description 33
- 239000000758 substrate Substances 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 26
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 18
- 125000005647 linker group Chemical group 0.000 claims description 15
- 125000003107 substituted aryl group Chemical group 0.000 claims description 15
- AFNOHTDETQTADW-YLRIPHBZSA-N 2-azido-n-[(3s,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound OC[C@H]1OC(O)[C@@H](NC(=O)CN=[N+]=[N-])[C@@H](O)[C@@H]1O AFNOHTDETQTADW-YLRIPHBZSA-N 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000005907 alkyl ester group Chemical group 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 230000004060 metabolic process Effects 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 210000003850 cellular structure Anatomy 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 150000007970 thio esters Chemical class 0.000 claims description 7
- 150000001350 alkyl halides Chemical class 0.000 claims description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 150000007860 aryl ester derivatives Chemical class 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 150000004702 methyl esters Chemical class 0.000 claims description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 3
- 150000001299 aldehydes Chemical class 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 150000003461 sulfonyl halides Chemical class 0.000 claims description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 2
- PAERYIZRYCNIKO-QTVWNMPRSA-N (3S,4R,5S,6R)-3-amino-2-azido-6-(hydroxymethyl)oxane-2,4,5-triol Chemical compound N(=[N+]=[N-])C1(O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO PAERYIZRYCNIKO-QTVWNMPRSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000019522 cellular metabolic process Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 38
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 11
- 239000012467 final product Substances 0.000 abstract description 8
- 239000006227 byproduct Substances 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 6
- 125000001424 substituent group Chemical group 0.000 abstract description 6
- 229920000642 polymer Polymers 0.000 abstract description 4
- 238000009833 condensation Methods 0.000 abstract description 3
- 230000005494 condensation Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 62
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 41
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- 239000012043 crude product Substances 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 17
- 239000010409 thin film Substances 0.000 description 17
- 229960002685 biotin Drugs 0.000 description 16
- 235000020958 biotin Nutrition 0.000 description 16
- 239000011616 biotin Substances 0.000 description 16
- 150000002576 ketones Chemical class 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000000975 dye Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 108090000288 Glycoproteins Proteins 0.000 description 11
- 102000003886 Glycoproteins Human genes 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 238000000451 chemical ionisation Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000003800 Staudinger reaction Methods 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 8
- 108010081400 fluorescein isothiocyante avidin Proteins 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 150000003003 phosphines Chemical class 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 7
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
- 108090001008 Avidin Proteins 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 238000010265 fast atom bombardment Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- KRCVJTNGGWBYEW-REOHCLBHSA-N (2s)-2-(2-diazohydrazinyl)propanoic acid Chemical compound OC(=O)[C@H](C)NN=[N+]=[N-] KRCVJTNGGWBYEW-REOHCLBHSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 6
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 230000008707 rearrangement Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- BYCLVUPPFSCPPQ-GSZUSEIOSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-(2-iodoacetyl)pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(C(=O)O)C(=O)CI)SC[C@@H]21 BYCLVUPPFSCPPQ-GSZUSEIOSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 229920001222 biopolymer Polymers 0.000 description 4
- 230000006287 biotinylation Effects 0.000 description 4
- 238000007413 biotinylation Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 125000005629 sialic acid group Chemical group 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- QISAUDWTBBNJIR-UHFFFAOYSA-N 2-phenylmethoxyacetyl chloride Chemical compound ClC(=O)COCC1=CC=CC=C1 QISAUDWTBBNJIR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- OVRNDRQMDRJTHS-ZTVVOAFPSA-N N-acetyl-D-mannosamine Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-ZTVVOAFPSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- QPECWWIZMZHSDR-UHFFFAOYSA-N diphenylphosphanylmethanol Chemical compound C=1C=CC=CC=1P(CO)C1=CC=CC=C1 QPECWWIZMZHSDR-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000005538 phosphinite group Chemical group 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000006557 surface reaction Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 2
- RBNSZWOCWHGHMR-UHFFFAOYSA-N (2-iodoacetyl) 2-iodoacetate Chemical compound ICC(=O)OC(=O)CI RBNSZWOCWHGHMR-UHFFFAOYSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 2
- OXWAMAJGEKUFTM-TVCQNHEDSA-N OC[C@H]1OC(O)[C@@H](NC(=O)CCN=[N+]=[N-])[C@@H](O)[C@@H]1O Chemical compound OC[C@H]1OC(O)[C@@H](NC(=O)CCN=[N+]=[N-])[C@@H](O)[C@@H]1O OXWAMAJGEKUFTM-TVCQNHEDSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000003428 Staudinger Azide reduction reaction Methods 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000007819 coupling partner Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000008276 mannosamines Chemical class 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- OAADXJFIBNEPLY-UHFFFAOYSA-N methoxy(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(OC)C1=CC=CC=C1 OAADXJFIBNEPLY-UHFFFAOYSA-N 0.000 description 2
- RXYCUKSOYJWGPE-UHFFFAOYSA-N methyl 2-azidoacetate Chemical compound COC(=O)CN=[N+]=[N-] RXYCUKSOYJWGPE-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- MDDUHVRJJAFRAU-YZNNVMRBSA-N tert-butyl-[(1r,3s,5z)-3-[tert-butyl(dimethyl)silyl]oxy-5-(2-diphenylphosphorylethylidene)-4-methylidenecyclohexyl]oxy-dimethylsilane Chemical compound C1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)C(=C)\C1=C/CP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 MDDUHVRJJAFRAU-YZNNVMRBSA-N 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- WNQGKLDRWPAZGJ-CBPJZXOFSA-N (3S,4R,5S,6R)-3-(2-diazohydrazinyl)-6-(hydroxymethyl)oxane-2,4,5-triol Chemical compound OC[C@H]1OC(O)[C@@H](NN=[N+]=[N-])[C@@H](O)[C@@H]1O WNQGKLDRWPAZGJ-CBPJZXOFSA-N 0.000 description 1
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- HKAVADYDPYUPRD-UHFFFAOYSA-N 1h-pyrazine-2-thione Chemical compound SC1=CN=CC=N1 HKAVADYDPYUPRD-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- CQXMHOZNZYSQLQ-UHFFFAOYSA-N 2-(iodomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CI CQXMHOZNZYSQLQ-UHFFFAOYSA-N 0.000 description 1
- MBQYGQMGPFNSAP-UHFFFAOYSA-N 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCN=[N+]=[N-] MBQYGQMGPFNSAP-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- PPXUUPXQWDQNGO-UHFFFAOYSA-N 2-azidoacetic acid Chemical compound OC(=O)CN=[N+]=[N-] PPXUUPXQWDQNGO-UHFFFAOYSA-N 0.000 description 1
- OBLNATYHUHRRBM-UHFFFAOYSA-N 2-chloro-4-(nitromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C[N+]([O-])=O)C=C1Cl OBLNATYHUHRRBM-UHFFFAOYSA-N 0.000 description 1
- FAQNRQQRXPAZHI-YLRIPHBZSA-N 2-iodo-n-[(3s,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound OC[C@H]1OC(O)[C@@H](NC(=O)CI)[C@@H](O)[C@@H]1O FAQNRQQRXPAZHI-YLRIPHBZSA-N 0.000 description 1
- ZTDKVQIYPZMDQC-STYVAPRTSA-N 2-phenylmethoxy-n-[(3s,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@H]1NC(=O)COCC1=CC=CC=C1 ZTDKVQIYPZMDQC-STYVAPRTSA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- QKOKLMFCKLEFDV-UHFFFAOYSA-N 3-amino-4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C=C1N QKOKLMFCKLEFDV-UHFFFAOYSA-N 0.000 description 1
- YIPVUXAMZQBALD-UHFFFAOYSA-N 3-azidopropanoic acid Chemical compound OC(=O)CCN=[N+]=[N-] YIPVUXAMZQBALD-UHFFFAOYSA-N 0.000 description 1
- DHXNZYCXMFBMHE-UHFFFAOYSA-N 3-bromopropanoic acid Chemical compound OC(=O)CCBr DHXNZYCXMFBMHE-UHFFFAOYSA-N 0.000 description 1
- AGYGRJJIWDNTLI-UHFFFAOYSA-N 3-iodo-4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C=C1I AGYGRJJIWDNTLI-UHFFFAOYSA-N 0.000 description 1
- FREZLSIGWNCSOQ-UHFFFAOYSA-N 3-methylbutanoyl 3-methylbutanoate Chemical class CC(C)CC(=O)OC(=O)CC(C)C FREZLSIGWNCSOQ-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- JLJZRAUDCHWQPS-NYONGVCJSA-N 4-oxo-n-[(3s,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]pentanamide Chemical compound CC(=O)CCC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O JLJZRAUDCHWQPS-NYONGVCJSA-N 0.000 description 1
- VESMEBBJISCMLQ-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;phosphane Chemical compound P.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 VESMEBBJISCMLQ-UFLZEWODSA-N 0.000 description 1
- QAYNSPOKTRVZRC-UHFFFAOYSA-N 99-60-5 Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1Cl QAYNSPOKTRVZRC-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- BXXLTVBTDZXPTN-UHFFFAOYSA-N COC(c(cccc1)c1I)=O Chemical compound COC(c(cccc1)c1I)=O BXXLTVBTDZXPTN-UHFFFAOYSA-N 0.000 description 1
- 0 COC(c1ccccc1*)=O Chemical compound COC(c1ccccc1*)=O 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- HGMISDAXLUIXKM-LIADDWGISA-N [(2r,3s,4r,5s)-3,4,6-triacetyloxy-5-[(2-azidoacetyl)amino]oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(OC(C)=O)[C@@H](NC(=O)CN=[N+]=[N-])[C@@H](OC(C)=O)[C@@H]1OC(C)=O HGMISDAXLUIXKM-LIADDWGISA-N 0.000 description 1
- CIJNVOSMYUVWLV-OCEBYYKGSA-N [(2r,3s,4r,5s)-3,4,6-triacetyloxy-5-[(2-phenylmethoxyacetyl)amino]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)OC(OC(C)=O)[C@H]1NC(=O)COCC1=CC=CC=C1 CIJNVOSMYUVWLV-OCEBYYKGSA-N 0.000 description 1
- OVPIZHVSWNOZMN-KJAHXBPPSA-N [(2r,3s,4r,5s)-5-acetamido-3,4,6-triacetyloxyoxan-2-yl]methyl acetate Chemical compound CC(=O)N[C@@H]1C(OC(C)=O)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OVPIZHVSWNOZMN-KJAHXBPPSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000032912 absorption of UV light Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001503 aryl iodides Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- FZIZEIAMIREUTN-UHFFFAOYSA-N azane;cerium(3+) Chemical compound N.[Ce+3] FZIZEIAMIREUTN-UHFFFAOYSA-N 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical class ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical group C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003125 jurkat cell Anatomy 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- VWTREAQKLNMBGC-UHFFFAOYSA-N methyl 2-diphenylphosphanylbenzoate Chemical group COC(=O)C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 VWTREAQKLNMBGC-UHFFFAOYSA-N 0.000 description 1
- SAWKFRBJGLMMES-UHFFFAOYSA-N methylphosphine Chemical group PC SAWKFRBJGLMMES-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- CPGRMGOILBSUQC-UHFFFAOYSA-N phosphoryl azide Chemical class [N-]=[N+]=NP(=O)(N=[N+]=[N-])N=[N+]=[N-] CPGRMGOILBSUQC-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GMRIOAVKKGNMMV-UHFFFAOYSA-N tetrabutylazanium;azide Chemical compound [N-]=[N+]=[N-].CCCC[N+](CCCC)(CCCC)CCCC GMRIOAVKKGNMMV-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5022—Aromatic phosphines (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18983700P | 2000-03-16 | 2000-03-16 | |
US189837P | 2000-03-16 | ||
PCT/US2001/008546 WO2001068565A2 (en) | 2000-03-16 | 2001-03-16 | Chemoselective ligation by use of a phosphine |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60120650D1 DE60120650D1 (de) | 2006-07-27 |
DE60120650T2 true DE60120650T2 (de) | 2007-05-31 |
Family
ID=22698968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60120650T Expired - Lifetime DE60120650T2 (de) | 2000-03-16 | 2001-03-16 | Chemoselektive anknüpfung durch verwendung eines phosphins |
Country Status (6)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010102997A2 (de) | 2009-03-09 | 2010-09-16 | Freie Universität Berlin | Mit einer phosphoramidat- und/oder phosphonamidgruppe modifizierte verbindung und deren verwendung |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6570040B2 (en) * | 2000-03-16 | 2003-05-27 | The Regents Of The University Of California | Chemoselective ligation |
AU6153001A (en) | 2000-05-12 | 2001-11-26 | Wisconsin Alumni Res Found | Ligation method and reagents to form an amide bond |
US7256259B2 (en) | 2000-05-12 | 2007-08-14 | Wisconsin Alumni Research Foundation | Methods for ligation of molecules to surfaces |
US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7173003B2 (en) * | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
ES2286386T3 (es) | 2002-03-28 | 2007-12-01 | Unilever N.V. | Dulce de hielo congelado. |
JP2005529166A (ja) * | 2002-06-07 | 2005-09-29 | ウィスコンシン アルムニ リサーチ ファウンデーション | ペプチドカップリングのための試薬の化学合成 |
DE60336555D1 (de) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
US20050233473A1 (en) * | 2002-08-16 | 2005-10-20 | Zyomyx, Inc. | Methods and reagents for surface functionalization |
KR20060003862A (ko) * | 2003-03-14 | 2006-01-11 | 네오스 테크놀로지스, 인크. | 수용성분기폴리머 및 그 접합체 |
US20040235027A1 (en) * | 2003-03-31 | 2004-11-25 | Regent Of The University Of California | Preparation and application of ligand-biopolymer conjugates |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
MXPA05011832A (es) * | 2003-05-09 | 2006-02-17 | Neose Technologies Inc | Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano. |
US9005625B2 (en) * | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
WO2005047245A2 (en) * | 2003-11-14 | 2005-05-26 | Wisconsin Alumni Research Foundation | Fluorescence assays with improved blocking groups |
US7070941B2 (en) * | 2003-11-17 | 2006-07-04 | Board Of Regents, The University Of Texas System | Methods and compositions for tagging via azido substrates |
US7842661B2 (en) * | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
EP1694347B1 (en) * | 2003-11-24 | 2013-11-20 | BioGeneriX AG | Glycopegylated erythropoietin |
US8633157B2 (en) * | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
KR101237884B1 (ko) * | 2003-12-03 | 2013-02-27 | 바이오제너릭스 에이지 | 글리코 peg화 과립구 콜로니 자극인자 |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US8361961B2 (en) * | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US20090292110A1 (en) * | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
WO2006021553A1 (en) * | 2004-08-23 | 2006-03-02 | Covalys Biosciences Ag | Method for protein purification and labeling based on a chemoselective reaction |
WO2006031811A2 (en) * | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
EP1799278A2 (en) | 2004-09-28 | 2007-06-27 | Baylor University | Spatially-defined modification of fresh tissue using covalent chemistry |
WO2006038185A2 (en) * | 2004-10-07 | 2006-04-13 | Koninklijke Philips Electronics N.V. | Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy |
WO2006042146A2 (en) * | 2004-10-07 | 2006-04-20 | Emory University | Multifunctional nanoparticles conjugates and their use |
ES2572779T3 (es) | 2004-10-29 | 2016-06-02 | Ratiopharm Gmbh | Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF) |
ATE534909T1 (de) | 2004-12-22 | 2011-12-15 | California Inst Of Techn | Verfahren zur proteomischen profilierung mithilfe nichtnatürlicher aminosäuren |
JP2008526864A (ja) * | 2005-01-06 | 2008-07-24 | ネオス テクノロジーズ インコーポレイテッド | 糖断片を用いる糖結合 |
WO2006074467A2 (en) * | 2005-01-10 | 2006-07-13 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
WO2006079364A1 (en) * | 2005-01-31 | 2006-08-03 | Stichting Voor De Technische Wetenschappen | Specific and mild peptide or amide bond cleavage |
GB0507123D0 (en) * | 2005-04-08 | 2005-05-11 | Isis Innovation | Method |
EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
US20110003744A1 (en) * | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20070134685A1 (en) * | 2005-09-06 | 2007-06-14 | Invitrogen Corporation | Control of chemical modification |
EP2026840A2 (en) * | 2005-10-04 | 2009-02-25 | Koninklijke Philips Electronics N.V. | Targeted imaging and/or therapy using the [3+2]-azide-alkyne cycloaddition |
JP2009512642A (ja) * | 2005-10-04 | 2009-03-26 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 画像及び治療におけるシュタウディンガー反応並びに画像及び治療に使用するキット |
US20100247433A1 (en) * | 2005-10-14 | 2010-09-30 | California Institute Of Technology | Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells |
US7910335B2 (en) * | 2005-10-27 | 2011-03-22 | President And Fellows Of Harvard College | Methods and compositions for labeling nucleic acids |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
US7465544B2 (en) * | 2006-01-11 | 2008-12-16 | Wisconsin Alumni Research Foundation | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use |
US8114636B2 (en) | 2006-02-10 | 2012-02-14 | Life Technologies Corporation | Labeling and detection of nucleic acids |
EP3438131B1 (en) | 2006-02-10 | 2022-03-16 | Life Technologies Corporation | Oligosaccharide modification and labeling of proteins |
CA2636621C (en) * | 2006-02-21 | 2013-06-25 | Huntsman International Llc | Process for making a polyisocyanurate composite |
EP1996609B1 (en) * | 2006-03-22 | 2016-08-03 | The Scripps Research Institute | Method of preparing glycopeptides |
RU2008142542A (ru) * | 2006-03-28 | 2010-05-10 | Конинклейке Филипс Электроникс Н.В. (Nl) | Применение лигирования штаудингера при сборке in vivo биологически активного соединения |
US20080280818A1 (en) * | 2006-07-21 | 2008-11-13 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
EP2068907B1 (en) * | 2006-10-04 | 2017-11-29 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
FI20075030A0 (fi) * | 2007-01-18 | 2007-01-18 | Suomen Punainen Risti Veripalv | Menetelmä solujen modifioimiseksi |
ES2406267T3 (es) * | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Métodos de tratamiento usando G-CSF glicopegilado |
EP2162535A4 (en) * | 2007-06-04 | 2011-02-23 | Novo Nordisk As | O-linked glycosylation using N-acetylglucosamine transferases |
JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | ヌクレオチド糖の改良製造法 |
US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CA2711503A1 (en) * | 2008-01-08 | 2009-07-16 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
US8034396B2 (en) * | 2008-04-01 | 2011-10-11 | Tyco Healthcare Group Lp | Bioadhesive composition formed using click chemistry |
WO2009140541A2 (en) | 2008-05-16 | 2009-11-19 | Life Technologies Corporation | Dual labeling methods for measuring cellular proliferation |
US8350014B2 (en) * | 2008-11-17 | 2013-01-08 | Wisconsin Alumni Research Foundation | Preparation of diazo and diazonium compounds |
US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
WO2010095053A2 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices |
US8968733B2 (en) * | 2009-02-21 | 2015-03-03 | Sofradim Production | Functionalized surgical adhesives |
CA2753165A1 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Compounds and medical devices activated with solvophobic linkers |
CA2753189A1 (en) | 2009-02-21 | 2010-08-26 | Nadya Belcheva | Medical devices having activated surfaces |
US9039979B2 (en) | 2009-02-21 | 2015-05-26 | Sofradim Production | Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices |
AU2010215202A1 (en) | 2009-02-21 | 2011-10-13 | Covidien Lp | Crosslinked fibers and method of making same using UV radiation |
EP2398523B1 (en) | 2009-02-21 | 2018-04-04 | Covidien LP | Medical devices having activated surfaces |
EP2398845B1 (en) | 2009-02-21 | 2017-12-13 | Sofradim Production | Amphiphilic compounds and self-assembling compositions made therefrom |
US8663689B2 (en) * | 2009-02-21 | 2014-03-04 | Sofradim Production | Functionalized adhesive medical gel |
WO2010095056A2 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Medical devices with an activated coating |
US8877170B2 (en) * | 2009-02-21 | 2014-11-04 | Sofradim Production | Medical device with inflammatory response-reducing coating |
US8535477B2 (en) * | 2009-02-21 | 2013-09-17 | Sofradim Production | Medical devices incorporating functional adhesives |
US8648144B2 (en) | 2009-02-21 | 2014-02-11 | Sofradim Production | Crosslinked fibers and method of making same by extrusion |
US8512728B2 (en) | 2009-02-21 | 2013-08-20 | Sofradim Production | Method of forming a medical device on biological tissue |
WO2011045418A1 (en) * | 2009-10-16 | 2011-04-21 | Dsm Ip Assets B.V. | Azido alkanoic acids and derivatives thereof in feed for reducing methane formation emanating from the digestive activities of ruminants |
FR2952058B1 (fr) | 2009-10-29 | 2013-10-04 | Centre Nat Rech Scient | Procede de ligation native de polypeptides |
CA2794336A1 (en) * | 2010-03-25 | 2011-09-29 | Sofradim Production | Surgical fasteners and methods for sealing wounds |
US8795331B2 (en) | 2010-03-25 | 2014-08-05 | Covidien Lp | Medical devices incorporating functional adhesives |
EP2588525A4 (en) | 2010-06-29 | 2015-06-10 | Covidien Lp | MICROWAVE POWERED REACTOR AND IN SITU IMPLANT TRAINING METHOD |
WO2012001532A2 (en) | 2010-07-01 | 2012-01-05 | Sofradim Production | Medical device with predefined activated cellular integration |
WO2012014080A2 (en) | 2010-07-27 | 2012-02-02 | Sofradim Production | Polymeric fibers having tissue reactive members |
KR20140016262A (ko) | 2011-01-14 | 2014-02-07 | 레드우드 바이오사이언스 인코포레이티드 | 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법 |
FR2971509B1 (fr) | 2011-02-16 | 2013-02-22 | Centre Nat Rech Scient | Procede de preparation de peptides par assemblage de multiples fragments peptidiques |
CN103502218B (zh) | 2011-03-04 | 2016-08-17 | 生命科技公司 | 用于缀合生物分子的化合物和方法 |
WO2012134925A1 (en) | 2011-03-25 | 2012-10-04 | Life Technologies Corporation | Heterobifunctional esters for use in labeling target molecules |
US20140170653A1 (en) | 2011-04-15 | 2014-06-19 | Life Technologies Corporation | Chemical ligation |
US9556195B2 (en) | 2011-09-12 | 2017-01-31 | The Regents Of The University Of California | Compositions and methods for quadricyclane modification of biomolecules |
FR2981352B1 (fr) | 2011-10-17 | 2015-07-03 | Centre Nat Rech Scient | Procede de synthese de proteines |
FR2988392B1 (fr) | 2012-03-21 | 2014-04-11 | Centre Nat Rech Scient | Procede de ligation native |
CN104704359A (zh) | 2012-10-25 | 2015-06-10 | 生命科技公司 | 糖蛋白酶介导位点特异性放射性标记的方法和组合物 |
WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
US9775928B2 (en) | 2013-06-18 | 2017-10-03 | Covidien Lp | Adhesive barbed filament |
CA2927806C (en) | 2013-11-27 | 2023-01-10 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
DE102013113156A1 (de) * | 2013-11-28 | 2015-05-28 | Freie Universität Berlin | Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese |
US9410958B2 (en) | 2014-03-25 | 2016-08-09 | The Regents Of The University Of California | Alkyne-activated fluorogenic azide compounds and methods of use thereof |
US20180215783A1 (en) * | 2015-08-13 | 2018-08-02 | The Regents Of The University Of California | Bioorthogonal reaction of an amine n-oxide and a boron agent |
US10195283B2 (en) | 2016-03-18 | 2019-02-05 | R.P. Scherer Technologies, Llc | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate |
WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
EP3472210A1 (en) | 2016-06-17 | 2019-04-24 | Life Technologies Corporation | Site-specific crosslinking of antibodies |
US10814036B2 (en) | 2016-11-07 | 2020-10-27 | Baylor University | Drug-eluting live tissue for transplantation |
CA3049449A1 (en) | 2017-01-18 | 2018-07-26 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
KR20220004947A (ko) | 2019-04-29 | 2022-01-12 | 일루미나, 인코포레이티드 | 신속한 인큐베이션 및 핵산 풍부화에 의한 미생물 샘플의 확인 및 분석 |
CN116710146A (zh) | 2020-04-03 | 2023-09-05 | 威特拉公司 | 抗体分子-药物偶联物及其用途 |
EP4108669A1 (en) * | 2021-06-24 | 2022-12-28 | Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. | Carbohydrate derivatives and kits for cell surface labeling |
US11879010B2 (en) | 2021-09-30 | 2024-01-23 | The Charlotte Mecklenburg Hospital Authority | Methods and compositions for pretargeted immunotherapy |
CN117736135B (zh) * | 2024-02-19 | 2024-05-07 | 西北农林科技大学深圳研究院 | 一种蛋白质位点特异性修饰的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4321366A (en) * | 1978-05-12 | 1982-03-23 | Research Corporation | Process of preparing 2-azido-2-deoxyarabinofuranosyl halides |
US4292437A (en) * | 1979-06-27 | 1981-09-29 | E. I. Du Pont De Nemours And Company | Preparation of isobutyric acid and esters |
CA1340899C (en) | 1988-03-09 | 2000-02-15 | Andre Bardy | Procede de preparation de complexes nitruro 99m tc, 186 re ou 188 re utilisables comme produits radiopharmaceutiques |
DE4325816A1 (de) | 1993-07-31 | 1995-02-02 | Hoechst Ag | Sekundäre und tertiäre Phosphane und Verfahren zu ihrer Herstellung |
US5874628A (en) * | 1997-03-26 | 1999-02-23 | Monsanto Company | Method for preparation of tertiary phosphines via nickel-catalyzed cross coupling |
US6570040B2 (en) * | 2000-03-16 | 2003-05-27 | The Regents Of The University Of California | Chemoselective ligation |
AU6153001A (en) | 2000-05-12 | 2001-11-26 | Wisconsin Alumni Res Found | Ligation method and reagents to form an amide bond |
-
2001
- 2001-03-16 US US09/810,864 patent/US6570040B2/en not_active Expired - Lifetime
- 2001-03-16 AT AT01957599T patent/ATE329925T1/de not_active IP Right Cessation
- 2001-03-16 AU AU2001281463A patent/AU2001281463A1/en not_active Abandoned
- 2001-03-16 DE DE60120650T patent/DE60120650T2/de not_active Expired - Lifetime
- 2001-03-16 EP EP01957599A patent/EP1263771B1/en not_active Expired - Lifetime
- 2001-03-16 WO PCT/US2001/008546 patent/WO2001068565A2/en active IP Right Grant
-
2003
- 2003-03-06 US US10/384,099 patent/US7122703B2/en not_active Expired - Lifetime
-
2005
- 2005-01-19 US US11/039,478 patent/US7923582B2/en not_active Expired - Fee Related
-
2006
- 2006-04-20 US US11/408,605 patent/US7667012B2/en not_active Expired - Lifetime
- 2006-09-19 US US11/533,129 patent/US7939626B2/en not_active Expired - Lifetime
-
2007
- 2007-10-18 US US11/874,548 patent/US7838665B2/en not_active Expired - Fee Related
-
2011
- 2011-03-08 US US13/043,274 patent/US8076496B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010102997A2 (de) | 2009-03-09 | 2010-09-16 | Freie Universität Berlin | Mit einer phosphoramidat- und/oder phosphonamidgruppe modifizierte verbindung und deren verwendung |
US8575282B2 (en) | 2009-03-09 | 2013-11-05 | Freie Universitaet Berlin | Compound modified by a phosphoramidate and/or phosphonamide group and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20110236930A1 (en) | 2011-09-29 |
US8076496B2 (en) | 2011-12-13 |
US7923582B2 (en) | 2011-04-12 |
US20070037964A1 (en) | 2007-02-15 |
US7122703B2 (en) | 2006-10-17 |
US20080214801A1 (en) | 2008-09-04 |
US7939626B2 (en) | 2011-05-10 |
AU2001281463A1 (en) | 2001-09-24 |
US6570040B2 (en) | 2003-05-27 |
EP1263771A2 (en) | 2002-12-11 |
US20050148032A1 (en) | 2005-07-07 |
US7838665B2 (en) | 2010-11-23 |
US20030199084A1 (en) | 2003-10-23 |
US7667012B2 (en) | 2010-02-23 |
US20020016003A1 (en) | 2002-02-07 |
WO2001068565A2 (en) | 2001-09-20 |
ATE329925T1 (de) | 2006-07-15 |
WO2001068565A3 (en) | 2002-05-23 |
US20060276658A1 (en) | 2006-12-07 |
EP1263771B1 (en) | 2006-06-14 |
DE60120650D1 (de) | 2006-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60120650T2 (de) | Chemoselektive anknüpfung durch verwendung eines phosphins | |
DE60011053T2 (de) | An phosphocholin gebundene prodrug-derivate | |
EP1867638A1 (de) | Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf | |
DE69937108T2 (de) | Verbindungen und Methoden zum Nachweis von Biomolekülen | |
EP0133674B1 (de) | Neue Nitroxylverbindungen, Verfahren zu deren Herstellung und diese enthaltende diagnostische Mittel | |
DE69725611T2 (de) | Nicht-Nukleotid verknüpfende Reagentien | |
BRPI0713961A2 (pt) | compostos fosfinatos antivirais | |
DE60110127T2 (de) | Ligationsverfahren und reagenzien zur bildung einer amid-bindung | |
EP0429611A1 (de) | Aminoalkylmaleimide und davon abgeleitete hapten- und antigenderivate sowie konjugate mit peptiden oder proteinen | |
EP0060999B1 (de) | Galactopyranoside Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antigene oder Immunadsorbentien | |
AT390619B (de) | Verfahren zur herstellung von neuen prolinderivaten | |
DE2521523A1 (de) | Lactamverbindungen und konjugate | |
EP0049860A1 (de) | Verfahren zur Herstellung von reaktiven, kupplungsfähigen Derivaten der Schilddrüsenhormone T3 und T4 und deren Verwendung | |
DE60005788T2 (de) | Phosphinic pseudopeptide als matrix metalloprotease-inhibitoren | |
DE60305940T2 (de) | Modifizierte therapeutische mittel | |
WO2011101445A1 (de) | HOCHAFFINE MULTIVALENTE CHELATORVERBINDUNGEN (MCHs) UND DEREN VERWENDUNG ZUR STRUKTUR- UND FUNKTIONSANALYSE VON ZIELMOLEKÜLEN | |
DD217210A1 (de) | Verfahren zur herstellung von l-alanyl-d-isoglutaminyl-adamantylamid | |
Nieto‐García et al. | The Staudinger Ligation | |
EP0230056B1 (de) | Neue Thyroninderivate | |
DE60005534T2 (de) | Verfahren zur kupplung zwischen einem peptid und mindestens einer weiteren verbindung in lösung und verwendungen davon | |
Saxon et al. | Chemoselective ligation | |
WO2003040093A2 (de) | Isotopencodierte affinitätsmarker 2 | |
EP2406273A2 (de) | Mit einer phosphoramidat- und/oder phosphonamidgruppe modifizierte verbindung und deren verwendung | |
EP0089693A1 (de) | Steroidester von N-(2-Halogenethyl)-N-nitroso-carbamoyl-aminosäuren und deren Peptiden, sowie Verfahren zu deren Herstellung | |
Baskin | Development of copper-free click chemistry and application to imaging glycans in living systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |